



PATENT
Attorney Docket 056100-5020-01

#320
Dia
3/22/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Susan M. DYMECKI *et al.*)
Application No. 08/866,279) Group Art Unit: 1632
Filed: May 30, 1997) Examiner: Anne Marie Baker
For: **USE OF FLP RECOMBINASE**)
IN MICE)

PRELIMINARY AMENDMENT

Prior to examination, please amend this application as follows:

In the claims:

Please enter the following amended claims prior to prosecution:

50. (Amended) The transgenic mouse according to claim 12, wherein transcription of said another transgene is controlled by a regulatory region selected from the group consisting of regulatory regions from the genes encoding β -actin, phosphoglycerate kinase, HMG-CoA reductase, major histocompatibility complex class I, β 2-microglobulin, HSV thymidine kinase, Rous Sarcoma Virus regulatory elements, CMV intermediate early gene, and SV40 origin.

e1 sub 3 51. (Amended) The transgenic mouse according to claim 15, wherein said genes controlling differentiation of a cell or development of an organism are selected from the group consisting of genes encoding adhesion molecules, cyclin kinase inhibitors, Wnt family members, Pax family members, Winged helix family members, Hox family members, cytokines, interleukins, growth/differentiation factors and their receptors, kinases, phosphatases, metabolic enzymes, and antigen receptors.

Kindly consider the following new claims:

e2 sub 4 52. (New) A transgenic mouse comprising an Flp transgene integrated into the genome of the transgenic mouse, wherein the Flp transgene is expressed from a tissue specific or a developmental stage specific promoter in at least one cell of the transgenic mouse at a level sufficient to catalyze recombination between two FLP-recognition sequences in direct repeat orientation in said cell.